Uncategorized

Investors Scene: Mydecine Innovations Group (CSE:MYCO) (OTC:MYCOF) CSO Interview

[vc_row][vc_column][vc_column_text]
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Hey, everyone, welcome back to Investors Scene I’m Jeremy Szafron. Now, we had a doctor Rakesh on the show talking about a company called Mydecine. And it’s an incredible story. And today, I’m excited to introduce to you the Co-founder and the Chief Science Officer, Rob Roscow, joining us now. Rob? – Thanks, Jeremy for having me. I’m excited to talk to you today. – Yeah, I’m pretty excited too. I mean, it’s a hell of a story. The company is doing remarkably well on this side of a the operations, we’re talking about these real compounds. I know that you’re a geneticist by trade, you also have an incredible amount of experience between Canopy Growth and many others here. And so, let’s talk a little bit about why Mydecine. You’re the co-founder here, let’s talk about the company. – Absolutely. Mydecine was founded really on the exciting potential to develop the current clinical trial data, and excitement around the psychedelics space. And really, assistance and betterment of mental health therapy with psychedelics. And really to take the increasing interest in the general public and run forward with that. The situation currently is really exciting because there’s almost a perfect storm brewing of public interest in the space. And really a desire to answer these questions that have been long-standing. And then really most importantly, the medical science is catching up with this public desire and really enabling this to move forward quickly. And so, you know that climate brewing was really what got me personally excited in this space, and is really a lot of the backstory behind why we founded the company. – You know, we’re talking to Dr. Rakesh yesterday and he was really talking about the fact that obviously, this is a destigmatized arena now, right. We’re seeing state to state start to be open to what this looks like. Mental health has never been more at the forefront of what we care about, thank goodness, it’s about time. And so let’s talk about then, these unique medical compounds and how we get there. I mean Mydecine is very– an interesting company in that their IP is going to be around creating these molecules as well. So let’s talk about your role here. – Yeah, so what you’re highlighting there’s definitely an interesting situation. What we have is effectively a product of nature that’s showing a really, really strong promise. But it has not been really thought of, and how do you take this product of nature and make it most useful in a medical context. So I really view my role as a chief science officer is, how do we actually do that mechanistically. And this is something where we can take the template that we have with psilocybin, already really strong medical promise. And we can think about, well, how do we make that, in a stepwise fashion, more compatible with use in therapy, use in medical practice. And what this really looks like is being able to control doseability, to control potency of the medication. And then also to understand when and where to best use it, to be able to monitor the patients in accordance with the use here. And use it at a most appropriate time. And the exciting thing for the company is that, this is all very expensive work to do. And because it’s novel application of these concepts, really, it describes a nice patentable roadmap as to how we actually do this. You know, the patents really allow us to enable the work, fund the work, and then secure the value of the work in the long run. So it’s an exciting place to be working as a scientist right now. With the ability to see the pathway well into the future. – You know, we’ve seen it with the cannabis sector, obviously, where we’ve been able to really grab a compound, figure out what that cannabinoid is, and then put it into other products. Similar to anything in the pharmaceutical industry, I’m curious as to what that process looks like here. When you’re talking about things like psilocybin, MDMA. When you’re talking about taking the dose down to make it something that obviously has huge efficacy, but only a shorter period of time. What’s that scientific place look like for you? In the most layman terms, if you will. – Absolutely. So the comparison to cannabis is actually a really nice one. I kind of think of the space around medical use of tryptamine, psilocybin being an example there, as really similar to the medical use of cannabinoids in its maturity. But 10 or 20 years less so. And so if we think about the analogy further, you know you have a prime compound in cannabis, THC, but you have all these minor cannabinoids that are now showing increasing medical interest, medical efficacy, slight differences compared to the primary component. And this diversity also exists in psilocybin-producing mushrooms. And so this is something that as a company in the long run, we’re really looking at that diversity, and it’s partly that diversity that allows this tunability that I was mentioning earlier. – It’s an interesting one. I mean, I could talk about these types of things all day. It blows my mind, the fact that we can isolate something and then try to put it into a better situation. And then in turn help people. You know the true, true comparable here in terms of this is, you’re talking about companies like MAPS, for instance, doing research. You know, you’re working with larger universities here, you’re also– got some great clinical trials going. Can you talk a little bit about those? – Absolutely. And so as a company, we really view the use of psilocybin as a completely medical avenue. And so, to that end, we really spent the last year since founding the company, putting together a large group of clinical trials that are very pointed at the question of, how do you best use this in combination with therapy. So if you look at our PTSD trials as an example, those are very much set out to one to the next, to the next, to iteratively ask these questions. What are the best styles of therapy to match with psilocybin assistance? How often do you use the psilocybin in these sorts of therapy situations? And so we’re really looking at that in a pointed fashion with the idea of being able to make that repeatable, and then scalable to a large PTSD community, which is very much in need. And so that’s something that we’re effectively pointing in that direction. The second avenue that we’re looking at there, is we’re sponsoring a number of, what I would say, preclinical stage trials, and the idea here is to understand what’s the lowest therapeutic dosage here. And so, similar to our theme of making these therapies more usable in a medical context, understanding the lowest dosage, and then the minimal amount of other effects necessary, is really a prime interest and is really an open question in the field. So this is why we’re, for instance, sponsoring microdosing research in London and Sydney right now. – Yeah you know, you mentioned it from the top, we’re really at the tip of the iceberg here. You know, you’re just getting started. I know you’re the co-founder here, when you look back to when you started this company to now. How excited are you, Rob? – I’m incredibly excited. I mean the amount of interest that we’ve seen build over the last year. The amount of new people getting excited about the space. Especially from more traditional pharmaceutical type camps, is really exciting to me. Because this is a category of compounds where there’s just such a huge medical potential. And it’s really been underserved with research and business interests. And so the fact that those two have been really continually building over the last year is incredibly exciting to me. Because it speaks well for the ability to continue to do this quickly into the future. And then I also kind of compare back to my experience in the cannabis space, which was also a very exciting startup space. But I always kind of make the comparison, this is almost moving four to six times faster than the cannabis space was in 2015, 2016, 2017. It’s very pointed and very accelerated in a clinical focused and facing way. And so that almost provides more focus to the industry in a way that makes it move faster. So it’s exciting, it’s very exciting. – Yeah, absolutely. And you know that every pharmaceutical company right now is having these discussions silently in their boardroom. Chief Science Officer Rob Brodsky joining us now from Colorado. Thanks for being on the show, and looking forward to having you back on. – Awesome. Thank you so much, Jeremy Looking forward– – Thanks.   [/vc_column_text][/vc_column][/vc_row]

Related Articles

Back to top button